|
[1]
|
Lchelt, U. and Wagner, E. (2015) Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond). Chemical Reviews, 115, 11043-11078. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Kurreck, J. (2003) Antisense Tech-nologies. Improvement through Novel Chemical Modifications. European Journal of Biochemistry, 270, 1628-1644. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Moreno, P.M.D. and Pêgo, A.P. (2014) Therapeutic Anti-sense Oligonucleotides against Cancer: Hurdling to the Clinic. Frontiers in Chemistry, 2, Article No. 87. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Hu, B., Zhong, L., Weng, Y., et al. (2020) Therapeutic SiRNA: State of the Art. Signal Transduction and Targeted Therapy, 5, Article No. 101. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Roberts, T.C., Langer, R. and Wood, M.J.A. (2020) Advances in Oligonucleotide Drug Delivery. Nature Reviews Drug Discovery, 19, 673-694. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Chen, D., Liu, X., Lu, X., et al. (2023) Nanoparticle Drug Deliv-ery Systems for Synergistic Delivery of Tumor Therapy. Frontiers in Pharmacology, 16, Article ID: 1111991. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Ulldemolins, A., Seras-Franzoso, J., Andrade, F., et al. (2021) Perspectives of Nano-Carrier Drug Delivery Systems to Overcome Cancer Drug Resistance in the Clinics. Cancer Drug Resistance, 4, 44-68. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Wei, G., Wang, Y., Yang, G., et al. (2021) Recent Progress in Nano-medicine for Enhanced Cancer Chemotherapy. Theranostics, 11, 6370-6392. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Sheoran, S., Arora, S., Samsonraj, R., et al. (2022) Lipid-Based Nanopar-ticles for Treatment of Cancer. Heliyon, 8, E09403. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Setten, R.L., Rossi, J.J. and Han, S.P. (2019) The Current State and Future Directions of RNAi-Based Therapeutics. Nature Reviews Drug Discovery, 18, 421-446. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Chen, Z., Kankala, R.K., Yang, Z., et al. (2022) Antibody-Based Drug Delivery Systems for Cancer Therapy: Mechanisms, Challenges, and Prospects. Theranostics, 12, 3719-3746. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Beck, A., Goetsch, L., Dumontet, C., et al. (2017) Strategies and Challenges for the Next Generation of Antibody-Drug Conjugates. Nature Reviews Drug Discov-ery, 16, 315-337. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Dugal-Tessier, J., Thirumalairajan, S. and Jain, N. (2021) Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates. Journal of Clinical Medicine, 10, Article No. 838. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Mullard, A. (2022) Antibody-Oligonucleotide Conju-gates Enter the Clinic. Nature Reviews Drug Discovery, 21, 6-8. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Maiti, R., Patel, B., Patel, N., et al. (2023) Antibody Drug Con-jugates as Targeted Cancer Therapy: Past Development, Present Challenges and Future Opportunities. Archives of Phar-macal Research, 46, 361-388. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Tang, H., Liu, Y., Yu, Z., et al. (2019) The Analysis of Key Factors Related to ADCs Structural Design. Frontiers in Pharmacology, 10, Article No. 373. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Dyne Therapeutics, Inc. (2023) Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy. US, US11638761B2.
|
|
[18]
|
van Geel, R., Wijdeven, M.A., Heesbeen, R., et al. (2015) Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. Bioconjugate Chemistry, 26, 2233-2242. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Lyon, R.P., Bovee, T.D., Do-ronina, S.O., et al. (2015) Reducing Hydrophobicity of Homogeneous Antibody-Drug Conjugates Improves Pharmaco-kinetics and Therapeutic Index. Nature Biotechnology, 33, 733-735. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Chau, C.H., Steeg, P.S. and Figg, W.D. (2019) Antibody-Drug Conjugates for Cancer. The Lancet, 394, 793-804. [Google Scholar] [CrossRef]
|
|
[21]
|
Tsuchikama, K. and An, Z. (2018) Antibody-Drug Conju-gates: Recent Advances in Conjugation and Linker Chemistries. Protein & Cell, 9, 33-46. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Drenkard, D., Becke, F., Langstein, J., et al. (2007) CD137 Is Expressed on Blood Vessel Walls at Sites of Infammation and Enhances Monocyte Migratory Activity. FASEB Journal, 21, 456-463. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Jain, N., Smith, S.W., Ghone, S., et al. (2015) Current ADC Linker Chemistry. Pharmaceutical Research, 32, 3526-3540. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Zacharias, N., Podust, V.N., Kajihara, K.K., et al. (2022) A Ho-mogeneous High-DAR Antibody-Drug Conjugate Platform Combining THIOMAB Antibodies and XTEN Polypeptides. Chemical Science, 13, 3147-3160. [Google Scholar] [CrossRef]
|
|
[25]
|
Kostova, V., et al. (2021) The Chemistry Behind ADCs. Pharmaceuti-cals, 14, 442-488. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Winkler, J. (2013) Oligonucleotide Conjugates for Therapeutic Applica-tions. Therapeutic Delivery, 4, 791-809. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Carter, P.J. and Senter, P.D. (2013) Antibody-Drug Conjugates in Cancer Therapy. Annual Review of Medicine, 64, 15-29. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Roberts, T.C., Langer, R., et al. (2020) Advances in Oligonucleotide Drug Delivery. Nature Reviews Drug Discovery, 19, 673-694. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Matsuda, Y. and Mendelsohn, B.A. (2021) An Over-view of Process Development for Antibody-Drug Conjugates Produced by Chemical Conjugation Technology. Expert Opinion on Biological Therapy, 21, 963-975. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Avidity Biosciences LLC (2018) Nucleic Acid-Polypeptide Compositions and Uses Thereof. AU, AU2017240799A1.
|
|
[31]
|
Arnold, A.E., Malek-Adamian, E., Le, P.U., et al. (2018) Antibody-Antisense Oligonucleotide Conjugate Downregulates a Key Gene in Glioblastoma Stem Cells. Molecu-lar Therapy—Nucleic Acids, 11, 518-527. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Tai, W., Li, J., Corey, E., et al. (2018) A Ribonucleoprotein Oc-tamer for Targeted SiRNA Delivery (Vol 2, Pg 326, 2018). Nature Biomedical Engineering, 2, 326-337. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Lu, H., Wang, D., Kazane, S., et al. (2013) Site-Specific Anti-body-Polymer Conjugates for SiRNA Delivery. Journal of the American Chemical Society, 135, 13885-13891. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Scheicher, B., Schachner-Nedherer, A.L. and Zimmer, A. (2015) Prota-mine-Oligonucleotide-Nanoparticles: Recent Advances in Drug Delivery and Drug Targeting. European Journal of Pharmaceutical Sciences, 75, 54-59. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Ruseska, I., Fresacher, K., Petschacher, C., et al. (2021) Use of Protamine in Nanopharmaceuticals—A Review. Nanomaterials (Basel), 11, 1508-1550. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Tang, B., Zaro, J.L., Shen, Y., et al. (2018) Acid-Sensitive Hybrid Polymeric Micelles Containing a Reversibly Activatable Cell-Penetrating Peptide for Tumor-Specific Cytoplasm Target-ing. Journal of Controlled Release, 279, 147-156. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Zhang, H., Mao, Y., Zhang, F., et al. (2014) The Inhibitory Effect of a New ScFv/TP Protein as SiRNA Delivery System to Target HWAPL in Cervical Carcinoma. Molecular and Cellular Biochemistry, 391, 77-84. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Bumer, N., Scheller, A., Wittmann, L., et al. (2022) Electrostatic Anti-CD33-Antibody-Protamine Nanocarriers as Platform for a Targeted Treatment of Acute Myeloid Leukemia. Journal of Hematology & Oncology, 15, 171-197. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Qian, L., Lin, X., Gao, X., et al. (2023) The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics. Chemical Reviews, 123, 7782-7853. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Dar, G.H., Gopal, V. and Rao, M. (2015) Confor-mation-Dependent Binding and Tumor-Targeted Delivery of SiRNA by a Designed TRBP2: Affibody Fusion Protein. Nanomedicine Nanotechnology Biology & Medicine, 11, 1455-1466. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Larance, R., Tripti, R., Devesh, R., et al. (2017) In Silico Analyses of Subtype Specific HIV-1 Tat-TAR RNA Interaction Reveals the Structural Determinants for Viral Activity. Frontiers in Microbiology, 8, 1467-1476. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Yang, Y., Zhu, H., Liu, D., et al. (2023) A Versatile Platform for the Tumor-Targeted Intracellular Delivery of Peptides, Proteins, and SiRNA. Advanced Functional Materials, 33, Article ID: 2301011. [Google Scholar] [CrossRef]
|
|
[43]
|
Dong, Y., Siegwart, D.J. and Anderson, D.G. (2019) Strategies, De-sign, and Chemistry in SiRNA Delivery Systems. Advanced Drug Delivery Reviews, 144, 133-147. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Bolcato-Bellemin, A.L., Bonnet, M.E., Creusat, G., et al. (2007) Sticky Overhangs Enhance SiRNA-Mediated Gene Silencing. Proceedings of the National Academy of Sciences of the United States of America, 104, 16050-16055. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Liu, T., Song, P., Märcher, A., et al. (2019) Selective Delivery of Doxorubicin to EGFR+ Cancer Cells by Cetuximab-DNA Conjugates. Chembiochem, 20, 1014-1018. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Zhang, J.X., Fang, J.Z., Duan, W., et al. (2018) Predicting DNA Hy-bridization Kinetics from Sequence. Nature Chemistry, 10, 91-98. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Wiener, J., Kokotek, D., Rosowski, S., et al. (2020) Preparation of Single- and Double-Oligonucleotide Antibody Conjugates and Their Application for Protein Analytics. Scientific Reports, 10, 1457-1468. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Benizri, S., Gissot, A., Martin, A., et al. (2019) Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications. Bioconjugate Chemistry, 30, 366-383. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Sugo, T., Terada, M., Oikawa, T., et al. (2016) Develop-ment of Antibody-SiRNA Conjugate Targeted to Cardiac and Skeletal Muscles. Journal of Controlled Release, 237, 1-13. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Malecova, B., Burke, R.S., Cochran, M., et al. (2023) Targeted Tissue Delivery of RNA Therapeutics Using Antibody-Oligonucleotide Conjugates (AOCs). Nucleic Acids Research, 51, 5901-5910. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Scott, C.C., Vacca, F. and Gruenberg, J. (2014) Endosome Maturation, Transport and Functions. Seminars in Cell & Developmental Biology, 31, 2-10. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Hassler, M.R., Turanov, A.A., Alterman, J.F., et al. (2018) Comparison of Partially and Fully Chemically-Modified SiRNA in Conjugate-Mediated Delivery in Vivo. Nucleic Acids Research, 46, 2185-2196. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Juliano, R.L. (2018) Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don’t. Nucleic Acid Therapeutics, 28, 166-177. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Dowdy, S.F., Setten, R.L., Cui, X.S., et al. (2022) Delivery of RNA Therapeutics: The Great Endosomal Escape! Nucleic Acid Therapeutics, 32, 361-368. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Mangla, P., Vicentini, Q. and Biscans, A. (2023) Therapeutic Oligonu-cleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking. Cells, 12, 2253-2291. [Google Scholar] [CrossRef] [PubMed]
|